Close Menu

NEW YORK – Invitae announced Wednesday evening that it has priced a $160 million public offering of 17,777,778 shares of common stock.

The offering was priced at $9.00 per share and is slated to close on April 6. Invitae is also granting underwriters a 30-day option to purchase an additional 2,666,666 shares of common stock at the same price.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.